Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer
- 23 February 2022
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 23 (2) , 254-267
Abstract
Opinion statement As the field of oncology enters the era of precision medicine and targeted therapies, we have come to realize that there may be no single “magic bullet” for patients with head and neck cancer. While immune check point inhibitors and some targeted therapeutics have shown great promise in improving oncologic outcomes, the current standard of care in most patients with head and neck squamous cell carcinoma (HNSCC) remains a combination of surgery, radiation, and/or cytotoxic chemotherapy. Nevertheless, advances in precision medicine, next-generation sequencing (NGS), and targeted therapies have a potential future in the treatment of HNSCC. These roles include increased patient treatment stratification based on predictive biomarkers or targetable mutations and novel combinatorial regimens with existing HNSCC treatments. There remain challenges to precision medicine and NGS in HNSCC, including intertumor and intratumor heterogeneity, challenging targets, and need for further trials validating the utility of NGS and precision medicine. Additionally, there is a need for evidence-based practice guidelines to assist clinicians on how to appropriately incorporate NGS in care for HNSCC. In this review, we describe the current state of precision medicine and NGS in HNSCC and opportunities for future advances in this challenging but important field.Keywords
Funding Information
- NIH (5K12CA138464-10)
This publication has 66 references indexed in Scilit:
- What is next generation sequencing?Archives of Disease in Childhood - Education & Practice Edition, 2013
- Genetic heterogeneity and cancer drug resistanceThe Lancet Oncology, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- The Mutational Landscape of Head and Neck Squamous Cell CarcinomaScience, 2011
- Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1Science, 2011
- Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period AnalysisThe Oncologist, 2010
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010
- A Phase 2 Trial of Surgery With Perioperative INGN 201 (Ad5CMV-p53) Gene Therapy Followed by Chemoradiotherapy for Advanced, Resectable Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx, and LarynxJAMA Otolaryngology–Head & Neck Surgery, 2009
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Transoral Robotic Surgery (TORS) for Base of Tongue NeoplasmsThe Laryngoscope, 2006